A prospective, observational, multicenter study assessing the safety and efficacy of von Willebrand Factor Concentrate (Wilate®) in von Willebrand disease patients in routine clinical use.

Trial Profile

A prospective, observational, multicenter study assessing the safety and efficacy of von Willebrand Factor Concentrate (Wilate®) in von Willebrand disease patients in routine clinical use.

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 11 Jan 2017

At a glance

  • Drugs Factor VIII/von Willebrand factor (Primary)
  • Indications Von Willebrand disease
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 11 Jan 2017 New trial record
    • 06 Dec 2016 Results of interim analysis (n=13)assessing safety and efficacy of Von Willebrand Factor Concentrate (Wilate) for von-Willebrand-disease patients in routine clinical settings presented at the 58th Annual Meeting and Exposition of the American Society of Hematology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top